Ryan T Hurt1, Jon O Ebbert2, Ivana T Croghan2, Darrell R Schroeder3, Richard D Hurt2, J Taylor Hays4. 1. Division of General Internal Medicine, Mayo Clinic, Rochester, MN, United States. 2. Division of Primary Care Internal Medicine, Mayo Clinic, Rochester, MN, United States; Nicotine Dependence Center, Mayo Clinic, Rochester, MN, United States. 3. Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, United States. 4. Division of General Internal Medicine, Mayo Clinic, Rochester, MN, United States; Nicotine Dependence Center, Mayo Clinic, Rochester, MN, United States. Electronic address: hays.taylor@mayo.edu.
Abstract
BACKGROUND: Tobacco use is prevalent among persons with alcohol abuse and dependence. Varenicline has been shown to be the most effective pharmacotherapy for smoking cessation and may decrease alcohol consumption. The purpose of this study was to evaluate the efficacy of 12 weeks of varenicline for increasing smoking abstinence rates in smokers with alcohol abuse or dependence. METHODS:Participants were eligible for enrollment if they were 18 years or older, smoked 10 or more cigarettes per day for at least 6 months, had current alcohol abuse or dependence, and were interested in quitting smoking. Participants were randomly assigned to receive 12 weeks of varenicline 1 mg twice daily or matching placebo. The primary end point was 7-day point prevalence smoking abstinence at week 12. RESULTS: The 7-day point prevalence smoking abstinence rate at 12 weeks was significantly higher with varenicline (n = 16) than placebo (n = 17) (43.8% vs 5.9%; P = .01). At 24 weeks, the 7-day point prevalence smoking abstinence rate was still significantly higher with varenicline than placebo (31.3% vs 0%; P = .02). At 12 weeks, mean (SD) drinks per drinking day was significantly lower with varenicline than placebo (5.7 [3.9] vs 9.0 [5.3] drinks; treatment effect estimate, -2.8 [90% CI, -6.6 to -1.0]). Adverse events were minor and comparable to varenicline clinical trials. CONCLUSIONS:Varenicline is safe and efficacious for increasing smoking abstinence rates in smokers with alcohol abuse or dependence. Varenicline may decrease alcohol consumption in this population of smokers.
RCT Entities:
BACKGROUND:Tobacco use is prevalent among persons with alcohol abuse and dependence. Varenicline has been shown to be the most effective pharmacotherapy for smoking cessation and may decrease alcohol consumption. The purpose of this study was to evaluate the efficacy of 12 weeks of varenicline for increasing smoking abstinence rates in smokers with alcohol abuse or dependence. METHODS:Participants were eligible for enrollment if they were 18 years or older, smoked 10 or more cigarettes per day for at least 6 months, had current alcohol abuse or dependence, and were interested in quitting smoking. Participants were randomly assigned to receive 12 weeks of varenicline 1 mg twice daily or matching placebo. The primary end point was 7-day point prevalence smoking abstinence at week 12. RESULTS: The 7-day point prevalence smoking abstinence rate at 12 weeks was significantly higher with varenicline (n = 16) than placebo (n = 17) (43.8% vs 5.9%; P = .01). At 24 weeks, the 7-day point prevalence smoking abstinence rate was still significantly higher with varenicline than placebo (31.3% vs 0%; P = .02). At 12 weeks, mean (SD) drinks per drinking day was significantly lower with varenicline than placebo (5.7 [3.9] vs 9.0 [5.3] drinks; treatment effect estimate, -2.8 [90% CI, -6.6 to -1.0]). Adverse events were minor and comparable to varenicline clinical trials. CONCLUSIONS:Varenicline is safe and efficacious for increasing smoking abstinence rates in smokers with alcohol abuse or dependence. Varenicline may decrease alcohol consumption in this population of smokers.
Authors: Lawrence V Rubinstein; Edward L Korn; Boris Freidlin; Sally Hunsberger; S Percy Ivy; Malcolm A Smith Journal: J Clin Oncol Date: 2005-10-01 Impact factor: 44.544
Authors: Douglas E Jorenby; J Taylor Hays; Nancy A Rigotti; Salomon Azoulay; Eric J Watsky; Kathryn E Williams; Clare B Billing; Jason Gong; Karen R Reeves Journal: JAMA Date: 2006-07-05 Impact factor: 56.272
Authors: Jon O Ebbert; Dorothy K Hatsukami; Ivana T Croghan; Darrell R Schroeder; Sharon S Allen; J Taylor Hays; Richard D Hurt Journal: JAMA Date: 2014-01-08 Impact factor: 56.272
Authors: John R Hughes; Josue P Keely; Ray S Niaura; Deborah J Ossip-Klein; Robyn L Richmond; Gary E Swan Journal: Nicotine Tob Res Date: 2003-02 Impact factor: 4.244
Authors: Robert M Anthenelli; Neal L Benowitz; Robert West; Lisa St Aubin; Thomas McRae; David Lawrence; John Ascher; Cristina Russ; Alok Krishen; A Eden Evins Journal: Lancet Date: 2016-04-22 Impact factor: 79.321
Authors: Cassie M Chandler; Sarah E Maggio; Hui Peng; Kimberly Nixon; Michael T Bardo Journal: Drug Alcohol Depend Date: 2020-04-25 Impact factor: 4.492
Authors: Robert A Waeiss; Christopher P Knight; Sheketha R Hauser; Lauren A Pratt; William J McBride; Zachary A Rodd Journal: Psychopharmacology (Berl) Date: 2019-02-13 Impact factor: 4.530
Authors: Lisa M Fucito; Ran Wu; Stephanie S O'Malley; Tess H Hanrahan; Jolomi T Ikomi; Srinivas Muvvala; Kathleen M Carroll; Ralitza Gueorguieva Journal: J Smok Cessat Date: 2020-03-18
Authors: Angela M Haeny; Ralitza Gueorguieva; LaTrice Montgomery; Krysten W Bold; Lisa M Fucito; Ran Wu; Srinivas B Muvvala; Allen Zweben; Stephanie S O'Malley Journal: Addict Behav Date: 2021-05-01 Impact factor: 4.591